Natalizumab is a monoclonal antibody that binds to alpha-4 integrin receptors on endothelial cells lining blood vessels. Integrins are a class of selective adhesion molecules composited of multiple subunits and, as a class, aid in the chemotaxis of leukocytes to sites of inflammation throughout the body.